Atypical antipsychotic drugs, quetiapine, iloperidone, and melperone, preferentially increase dopamine and acetylcholine release in rat medial prefrontal cortex: Role of 5-HT1A receptor agonism

Brain Research

Volumn 956, Issue 2, 2002, Pages 349-357

  Ichikawa, Junji ^a,b   Li, Zhu ^a   Dai, Jin ^a   Meltzer, Herbert Y ^a  

^a VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b Psychiatric Hospital at Vanderbilt   (United States)

Author keywords

5 HT1A receptor; Dopamine and acetylcholine release; Iloperidone; Medial prefrontal cortex and nucleus accumbens; Melperone; Quetiapine

Indexed keywords

ILOPERIDONE; MELPERONE; N [2 [4 (2 METHOXYPHENYL) 1 PIPERAZINYL]ETHYL] N (2 PYRIDYL)CYCLOHEXANECARBOXAMIDE; QUETIAPINE; SEROTONIN 1A RECEPTOR;

ACETYLCHOLINE RELEASE; ANIMAL TISSUE; ARTICLE; ASSAY; CONTROLLED STUDY; DOPAMINE RELEASE; DRUG EFFECT; MALE; MICRODIALYSIS; NONHUMAN; NUCLEUS ACCUMBENS; PREFRONTAL CORTEX; PRIORITY JOURNAL; RAT;

ACETYLCHOLINE; ANIMALS; ANTIPSYCHOTIC AGENTS; BUTYROPHENONES; CLOZAPINE; DIBENZOTHIAZEPINES; DOPAMINE; HALOPERIDOL; ISOXAZOLES; MALE; MICRODIALYSIS; NUCLEUS ACCUMBENS; PIPERIDINES; PREFRONTAL CORTEX; RATS; RATS, SPRAGUE-DAWLEY; RECEPTORS, SEROTONIN; RECEPTORS, SEROTONIN, 5-HT1;

EID: 0037195552     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03570-9     Document Type: Article

References (61)

1. Andersson J.L., Marcus M., Nomikos G.G., Svensson T.H. Prazosin modulates the changes in firing pattern and transmitter release induced by raclopride in the mesolimbic, but not in the nigrostriatal dopaminergic system. Naunyn-Schmiedebergs Arch. Pharmacol. 349:1994;236-243.
2. Arborelius L., Nomikos G.G., Hacksell U., Svensson T.H. (R)-8-OH-DPAT preferentially increases dopamine release in rat medial prefrontal cortex. Acta Psychiatr. Scand. 148:1993;465-466.
3. Arnt J., Skarsfeldt T. Do novel antipsychotics have similar pharmacological characteristics? A review of the evidence. Neuropsychopharmacology. 18:1998;63-101.
4. Arvanitis L.A., Miller B.G., the Seroquel Trial 13 Study Group . Multiple fixed doses of 'seroquel' (quetiapine) in patients with acute exacerbation of schizophrenia: a comparison with haloperidol and placebo. Biol. Psychiatr. 42:1997;233-246.
5. Barbato L., Monge A., Stocchi F., Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct. Neurol. 11:1996;201-207.
6. Bjerkenstedt L. Melperone in the treatment of schizophrenia. Acta Psychiatr. Scand. Suppl. 352:1989;35-39.
7. Bolden C., Cusack B., Richelson E. Antagonism by antimuscarinic and neuroleptic compounds at the five cloned human muscarinic cholinergic receptors expressed in Chinese hamster ovary cells. J. Pharmacol. Exp. Ther. 280:1992;576-580.
8. 2A/2C receptor antagonist, potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and nucleus accumbens, Neuropsychopharmacology 27 (2002) 430-441. ( http://www.acnp.org/citations/Npp022502247 ).
9. Borison R.L., Huff F.J., Griffiths L., Ramaswamy R., Shipley J.E. Efficacy of 4 mg/day and 8 mg/day iloperidone (HP 873) administered to schizophrenic patients for 42 days (Abstract). Psychopharmacol. Bull. 32:1996;416.
10. Bymaster F.P., Perry K.W., Nelson D.L., Wong D.T., Rasmussen K., Moore N.A., Calligaro D.O. Olanzapine: a basic science update. Br. J. Psychiatr. 174:(Suppl. 37):1999;36-40.
11. Corbett R., Hartman H., Kerman L.L., Woods A.T., Strupczenski J.T., Helsley G.C., Conway P.C., Dunn R.W. Effects of atypical antipsychotic agents on social behavior in rodents. Pharmacol. Biochem. Behav. 45:1993;9-17.
12. Davidson M., Brecher M., Kahn R., Stern R., Macaluso J. Iloperidone (HP 873): a study of safety and tolerance in schizophrenic inpatients (Abstract). Psychopharmacol. Bull. 30:1994;664.
13. 1A receptors in human post-mortem brain. Eur. J. Pharmacol. 386:1999;313-315.
14. 2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel) in patients with schizophrenia. Psychopharmacology. 135:1998;119-126.
15. Gudelsky G.A., Meltzer H.Y. Activation of tuberoinfundibular dopamine neurons following the acute administration of atypical antipsychotics. Neuropsychopharmacology. 2:1989;45-51.
16. 2 adrenoceptor blockade. Science. 286:1999;105-107.
17. Hirano H., Day J., Fibiger H.C. Serotonergic regulation of acetylcholine release in rat frontal cortex. J. Neurochem. 65:1995;1139-1145.
18. Ichikawa J., Meltzer H.Y. The effect of chronic atypical antipsychotic drugs and haloperidol in amphetamine-induced dopamine release in vivo. Brain Res. 574:1992;98-104.
19. Ichikawa J., Meltzer H.Y. Ziprasidone, a new antipsychotic, produces a preferential increase in extracellular dopamine (DA) utilization in the medial prefrontal cortex (mPFC). Soc. Neurosci. Abstr. 23:1997;161.7.
20. Ichikawa J., Meltzer H.Y. Relationship between dopaminergic and serotonergic neuronal activity in the frontal cortex and the action of typical and atypical antipsychotic drugs. Eur. Arch. Psychiat. Clin. Neurosci. 249:(Suppl. 4):1999;S90-S98.
21. 1A receptors on antipsychotic drug induced dopamine release in rat striatum and nucleus accumbens. Brain Res. 858:2000;252-263.
22. Ichikawa J., Dai J., Meltzer H.Y. Acetylcholinesterase inhibitors are neither necessary nor desirable for microdialysis studies of brain acetylcholine. Curr. Separ. 19:2000;37-44.
23. 1A receptor activation: a possible mechanism of atypical antipsychotic-induced cortical dopamine release. J. Neurochem. 76:2001;1521-1531.
24. 2A/2C receptor agonist, attenuates clozapine-induced cortical dopamine release. Brain Res. 907:2001;151-155.
25. Ichikawa J., Dai J., O'Laughlin I.A., Fowler W.L., Meltzer H.Y. Atypical, but not typical, antipsychotic drugs increase cortical acetylcholine release without an effect in the nucleus accumbens or striatum. Neuropsychopharmacology. 26:2002;325-339.
26. 2A receptors minimally contribute to clozapine-induced acetylcholine release in rat medial prefrontal cortex. Brain Res. 939:2002;34-42.
27. Jain K.K. An assessment of iloperidone for the treatment of schizophrenia. Exp. Opin. Invest. Drugs. 9:2000;2935-2943.
28. Kalkman H.O., Subramanian N., Hoyer D. Extended radioligand binding profile of iloperidone; a broad spectrum dopamine/serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 25:2001;904-914.
29. 1A receptor agonist, 8-OH-DPAT, locally administered into the dorsal raphe nucleus increased extracellular acetylcholine concentrations in the medial prefrontal cortex of conscious rats. Jpn. J. Neuropsychopharmacol. 21:2001;121-123.
30. Kongsamut S., Roehr J.E., Cai J., Hartman H.B., Weissensee P., Kerman L.L., Tang L., Sandrasagra A. Iloperidone binding to human and rat dopamine and 5-HT receptors. Eur. J. Pharmacol. 317:1996;417-423.
31. 1A receptor-mediated pathways by BAYx3702 in freely moving rats. Neurosci. Lett. 265:1999;33-36.
32. Kuroki T., Meltzer H.Y., Ichikawa J. Effect of antipsychotic drugs on extracellular dopamine levels in rat medial prefrontal cortex and nucleus accumbens. J. Pharmacol. Exp. Ther. 288:1999;774-781.
33. 2A receptor antagonism potentiates haloperidol-induced dopamine release in rat medial prefrontal cortex and inhibits that in the nucleus accumbens in a dose-dependent manner. Brain Res. 947:2002;157-165.
34. 1-adrenoceptor antagonism. Eur. Neuropsychopharmacol. 10:2000;245-253.
35. Meltzer H.Y., Matsubara S., Lee J.-C. Classification of typical and atypical antipsychotic drugs on the basis of dopamine D-1, D-2 and serotonin2 pKi values. J. Pharmacol. Exp. Ther. 251:1989;238-246.
36. Meltzer H.Y., Koenig J.I., Nash J.F., Gudelsky G.A. Melperone and clozapine: neuroendocrine effects of atypical neuroleptic drugs. Acta Psychiatr. Scand. Suppl. 352:1989;24-29.
37. Meltzer H.Y., McGurk S.R. The effects of clozapine, risperidone, and olanzapine on cognitive function in schizophrenia. Schizophr. Bull. 25:1999;233-255.
38. Meltzer H.Y. The role of serotonin in antipsychotic drug action. Neuropsychopharmacology. 21:(Suppl.):1999;S106-S115.
39. Meltzer H.Y., Sumiyoshi T., Jayathilake K. Melperone in the treatment of neuroleptic-resistant schizophrenia. Psychiatr. Res. 105:2001;201-209.
40. Moghaddam B., Bunney B.S. Acute effects of typical and atypical antipsychotic drugs on the release of dopamine from prefrontal cortex, nucleus accumbens, and striatum of the rat: an in vivo microdialysis study. J. Neurochem. 54:1990;1755-1760.
41. 35S]GTPγS. Eur. J. Pharmacol. 355:1998;245-256.
42. 3H]WAY100,635 binding affinity ratios: relationship to efficacy for G-protein activation. Eur. J. Pharmacol. 428:2001;177-184.
43. Paxinos G., Watson C. The Rat Brain in Stereotaxic Coordinates. 1986;Academic Press, New York.
44. Richelson E., Souder T. Binding of antipsychotic drugs to human brain receptors: Focus on newer generation compounds. Life Sci. 68:2000;29-39.
45. Robertson G.S., Matsubara H., Fibiger H.C. Induction patterns of Fos-like immunoreactivity in the forebrain as predictors of atypical antipsychotic activity. J. Pharmacol. Exp. Ther. 271:1994;1058-1066.
46. 1A receptor activation contributes to ziprasidone-induced dopamine release in rat prefrontal cortex. Biol. Psychiatr. 48:2000;229-237.
47. 1C receptors. J. Pharmacol. Exp. Ther. 260:1992;1361-1365.
48. 7 receptors. J. Pharmacol. Exp. Ther. 268:1994;1403-1410.
49. Saller C.F., Salama A.I. Seroquel: biochemical profile of a potential atypical antipsychotic. Psychopharmacology. 112:1993;285-292.
50. Schotte A., Janssen P.F.M., Gommeren W., Luyten W.H.M.L., van Gompel P., Lesage A.S., De Loore K., Leysen J.E. Risperidone compared with new and reference antipsychotic drugs: in vitro and in vivo receptor binding. Psychopharmacology. 124:1996;57-73.
51. Seeman P., Lee T., Chau-Wong M., Wong K. Antipsychotic drug doses and neuroleptic/dopamine receptors. Nature. 261:1976;717-719.
52. Small J.G., Hirsch S.R., Arvanitis L.A., MIller B.G., Link C.G.G., the Seroquel Study Group . Quetiapine in patients with schizophrenia: A high- and low-dose double-blind comparison with placebo. Arch. Gen. Psychiatr. 54:1997;549-557.
53. 1A receptor agonist, facilitates cortical acetylcholine release by a mechanism different from that of 8-OH-DPAT in awake rats. Neuropharmacology. 36:1997;1733-1739.
54. T. Sumiyoshi, K. Jayathilake, H.Y. Meltzer, The effect of melperone, an atypical antipsychotic drug, on cognitive function in schizophrenia, Schizophr. Res. (in press).
55. 2 receptor and alpha1-adrenoreceptor antagonism. J. Clin. Psychopharmacol. 15:1995;11S-18S.
56. Szewczak M.R., Corbett R., Rush D.K., Wilmot C.A., Conway P.G., Strupczewski J.T., Cornfeldt M. The pharmacological profile of iloperidone, a novel atypical antipsychotic agent. J. Pharmacol. Exp. Ther. 274:1995;1404-1413.
57. 2-adrenoceptor antagonist, (+)-efaroxan, enhances acetylcholine release in the rat cortex in vivo. Eur. J. Pharmacol. 277:1995;113-116.
58. Volonté M., Monferini E., Cerutti M., Fodritto F., Borsini F. BIMG 80, a novel potential antipsychotic drug: evidence for multireceptor actions and preferential release of dopamine in prefrontal cortex. J. Neurochem. 69:1997;182-190.
59. Wetzel H., Szegedi A., Hain Ch., Wiesner J., Schlegel S., Benkert O. Seroquel (ICI 204 636), a putative 'atypical' antipsychotic, in schizophrenia with positive symptomatology: results of an open clinical trial and changes of neuroendocrinological and EEG parameters. Psychopharmacology. 119:1995;231-238.
60. Zeng X.P., Le F., Richelson E. Muscarinic m4 receptor activation by some atypical antipsychotic drugs. Eur. J. Pharmacol. 321:1997;349-354.
61. 4 receptor agonist. Eur. J. Pharmacol. Mol. Pharmacol. 269:1994;R1-R2.